Apyx Medical (APYX) Stock Price, News & Analysis

Company Overview

Apyx Medical, Inc. is a global medical technology company specializing in the development and commercialization of advanced therapeutic and aesthetic solutions built on its proprietary radiofrequency (RF) energy platform. The company’s core technology harnesses the precision of RF energy in combination with helium to create a controlled plasma stream, enabling minimally invasive procedures with enhanced safety and predictable outcomes. By focusing on delivering clinically proven devices and consumables, Apyx Medical serves a diverse customer base that includes aesthetic surgeons, dermatologists, and general surgeons.

Among its flagship products is the Renuvion® system, which leverages helium plasma technology for subdermal skin rejuvenation and soft‐tissue contraction. Renuvion is widely used in aesthetic procedures such as body contouring, facial tightening, and correction of lax tissue, earning adoption in both free-standing surgical centers and hospital settings. In addition, the company offers the Helion™ platform for advanced electrosurgical ablation in open surgery, supporting a broad range of soft-tissue applications with consistent power delivery and precise hemostasis.

Originally founded as Bovie Medical Corporation over four decades ago, the company established a strong heritage in electrosurgical instrumentation before acquiring complementary RF and plasma technologies. In late 2020, shareholders approved the rebranding to Apyx Medical, reflecting the integration of innovative plasma solutions with the company’s longstanding electrosurgical heritage. This strategic evolution has expanded Apyx Medical’s product portfolio and deepened its research and development capabilities, reinforcing its commitment to improving patient outcomes through technology-driven solutions.

Headquartered in Clearwater, Florida, Apyx Medical maintains operations in key markets across North America, Europe, and the Asia-Pacific region. The company’s leadership team brings decades of combined experience in healthcare, medical devices, and regulatory affairs, driving execution of clinical studies and securing regulatory clearances globally. Focused on strategic partnerships and continuous innovation, Apyx Medical is positioned to advance its mission of enabling less invasive procedures and transforming standards of care in both aesthetic and general surgical specialties.

Key Stats

• Today's Range: $2.08 to $2.41
• 50-Day Range: $1.11 to $2.58
• 52-Week Range: $0.76 to $2.73
• Volume: 39,380 shs
• Average Volume: 85,811 shs
• Market Capitalization: $85.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Moderate Buy

Apyx Medical Stock Analysis - MarketRank™

Apyx Medical scored higher than 45% of companies evaluated by MarketBeat, and ranked 643rd out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Apyx Medical.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Apyx Medical are expected to grow in the coming year, from ($0.68) to ($0.33) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Apyx Medical is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Apyx Medical is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Apyx Medical has a P/B Ratio of 5.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.64% of the float of Apyx Medical has been sold short.

Short Interest Ratio / Days to Cover

Apyx Medical has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Apyx Medical has recently decreased by 2.63%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Apyx Medical does not currently pay a dividend.

Dividend Growth

Apyx Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.07

Percentage of Shares Shorted

0.64% of the float of Apyx Medical has been sold short.

Short Interest Ratio / Days to Cover

Apyx Medical has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Apyx Medical has recently decreased by 2.63%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Apyx Medical has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Apyx Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.20% of the stock of Apyx Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

55.33% of the stock of Apyx Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

APYX Stock Analysis - Frequently Asked Questions

How have APYX shares performed this year?

Apyx Medical's stock was trading at $1.58 at the beginning of the year. Since then, APYX stock has increased by 43.0% and is now trading at $2.26.

How were Apyx Medical's earnings last quarter?

Apyx Medical Corporation (NASDAQ:APYX) announced its quarterly earnings results on Thursday, May, 8th. The company reported ($0.10) earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.03. The company earned $9.43 million during the quarter, compared to analyst estimates of $9.39 million. Apyx Medical had a negative trailing twelve-month return on equity of 156.85% and a negative net margin of 42.37%.
Read the conference call transcript.

Who are Apyx Medical's major shareholders?

Top institutional investors of Apyx Medical include Silverberg Bernstein Capital Management LLC (2.37%) and Taylor Frigon Capital Management LLC (1.27%). Insiders that own company stock include Charles D Goodwin II and Todd Hornsby.
View institutional ownership trends.

How do I buy shares of Apyx Medical?

Shares of APYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Apyx Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Apyx Medical investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), AU Optronics (AUOTY), American Water Works (AWK) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:APYX
• CIK: 719135
• Web: www.apyxmedical.com
• Phone: (727) 384-2323
• Fax: 800-323-1640
• Employees: 270
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.55)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$23.46 million
• Net Margins: -42.37%
• Pretax Margin: -42.07%
• Return on Equity: -156.85%
• Return on Assets: -31.92%

Debt

• Debt-to-Equity Ratio: 3.21
• Current Ratio: 5.45
• Quick Ratio: 4.64

Sales & Book Value

• Annual Sales: $48.10 million
• Price / Sales: 1.72
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.38 per share
• Price / Book: 5.78

Miscellaneous

• Outstanding Shares: 37,790,000
• Free Float: 32,049,000
• Market Cap: $82.95 million
• Optionable: Optionable
• Beta: 1.31